According to Gram Research analysis, heart failure in older adults with preserved ejection fraction occurs because the heart’s mitochondria can’t properly clean up damaged proteins, even though they’re still making new mitochondrial structures normally. A 2026 study in aged mice found that reduced mitochondrial chaperones and proteases led to accumulation of broken proteins, reducing the heart’s energy production capacity by significant amounts and limiting exercise tolerance.
Researchers discovered that a common type of heart failure in older adults happens because the heart’s energy-producing structures, called mitochondria, can’t clean up and recycle their damaged proteins properly. Using mice that mimicked human heart disease, scientists found that the heart’s mitochondria had plenty of new protein-making machinery but lacked the cleanup crew needed to remove broken proteins. This protein buildup made the heart’s energy production drop significantly. The findings suggest that helping the heart’s mitochondria do better housekeeping might be a new way to treat this condition, which affects millions of older people worldwide.
Key Statistics
A 2026 research article in the American Journal of Physiology found that aged mice with heart failure with preserved ejection fraction showed significantly reduced mitochondrial respiratory capacity in left ventricular muscle fibers compared to healthy controls.
Proteomic analysis in the 2026 study revealed broad suppression of mitochondrial proteins supporting oxidative metabolism and organelle maintenance, while key regulators of mitochondrial biogenesis remained preserved, indicating impaired protein quality control rather than defective mitochondrial production.
The 2026 research documented increased accumulation of ubiquitinated mitochondrial proteins in the heart failure model, demonstrating that the protein cleanup system was overwhelmed despite normal mitochondrial biogenesis.
The Quick Take
- What they studied: Why the hearts of older people with a specific type of heart failure (called HFpEF) can’t pump blood as efficiently, focusing on the tiny energy factories inside heart cells
- Who participated: Aged mice (15 months old, equivalent to elderly humans) of both sexes that were given a high-fat diet and a drug that blocked a natural heart-protective chemical, creating a disease model matching human heart failure
- Key finding: Heart cells from these mice had severely reduced energy production capacity, caused by a buildup of broken proteins that the mitochondria couldn’t clean up properly, even though the cells were still making new mitochondrial proteins normally
- What it means for you: This research identifies a specific problem in heart failure that might be fixable with new treatments targeting protein cleanup in mitochondria. However, these are early findings in mice, and human treatments are still years away. Talk to your doctor about current proven heart failure treatments.
The Research Details
Scientists created a disease model in aging mice by combining two stressors: feeding them a high-fat diet and giving them a drug that blocks nitric oxide synthase, an enzyme that normally protects the heart. This two-hit approach mimicked the multiple health problems that older people with this type of heart failure typically have. The researchers then measured how well the heart’s mitochondria could produce energy using specialized equipment that directly measures oxygen consumption in muscle fibers. They also extracted mitochondria from heart cells and analyzed all the proteins inside them using advanced techniques called proteomics, which can identify thousands of proteins at once and determine which ones are present in abnormal amounts.
Understanding exactly what goes wrong inside the heart’s energy factories is crucial because it points to specific targets for new treatments. Previous research suggested mitochondria weren’t working well in this type of heart failure, but didn’t explain why. By pinpointing that the problem is broken protein cleanup rather than failure to build new mitochondria, researchers can now focus on developing drugs that improve the heart’s protein quality control system.
This study used a well-established animal model that closely mirrors human disease, included both male and female mice to check for sex differences, and employed state-of-the-art measurement techniques. The researchers used high-resolution respirometry, considered the gold standard for measuring mitochondrial energy production. The proteomics analysis identified thousands of proteins, providing comprehensive data. However, findings in mice don’t always translate directly to humans, and the study didn’t test any potential treatments.
What the Results Show
The aged mice with the induced heart failure showed preserved ejection fraction (meaning the heart’s pumping strength looked normal on standard tests) but had diastolic dysfunction (the heart couldn’t relax and fill properly between beats), matching human HFpEF. When researchers measured the mitochondria’s ability to produce energy, they found it was significantly reduced compared to healthy mice. The heart muscle fibers couldn’t generate enough energy to meet increased demands, explaining why these patients have reduced exercise capacity. Detailed protein analysis revealed that the mitochondria contained fewer proteins involved in energy production, including those needed for oxidative phosphorylation (the main energy-making process) and the TCA cycle (the metabolic pathway that fuels energy production). Surprisingly, proteins responsible for building new mitochondria were present at normal levels, ruling out defective mitochondrial biogenesis as the cause.
The most significant secondary finding was the dramatic reduction in mitochondrial chaperones and proteases, which are the cleanup proteins that remove damaged or misfolded proteins. This led to accumulation of ubiquitinated proteins (proteins marked for destruction but not removed), indicating a traffic jam in the protein quality control system. This protein backup appears to be the primary mechanism driving mitochondrial dysfunction rather than insufficient mitochondrial production.
Previous studies suggested mitochondrial dysfunction was important in HFpEF but didn’t identify the specific mechanism. This research builds on those findings by distinguishing between two possible causes: inadequate mitochondrial biogenesis versus impaired protein quality control. The finding that biogenesis is preserved but protein cleanup is impaired represents a significant shift in understanding and opens new therapeutic avenues that previous research hadn’t identified.
The study was conducted in mice, and results may not directly apply to humans due to differences in metabolism and disease progression. The research didn’t test whether improving mitochondrial protein cleanup actually reverses the heart failure, only that the problem exists. The study didn’t examine how this mechanism might differ between men and women, despite including both sexes. Additionally, the specific triggers that cause the protein cleanup system to fail remain unclear.
The Bottom Line
Current evidence-based treatments for HFpEF include managing blood pressure, controlling diabetes and obesity, and treating atrial fibrillation. This research suggests future treatments might target mitochondrial protein quality control, but such therapies are still in early research stages. Confidence level: High for the basic mechanism identified, but low for clinical applications at this time. Continue following your cardiologist’s current treatment recommendations.
This research is most relevant to older adults with HFpEF, their families, and healthcare providers treating this condition. It’s also important for researchers developing new heart failure drugs. People with other types of heart failure should consult their doctors about whether these findings apply to their situation.
This is fundamental research identifying a mechanism, not a clinical trial of a treatment. It typically takes 5 to 10 years to develop a drug based on such findings and another 5 to 10 years for clinical testing. Realistic timeline for new treatments reaching patients: 10 to 20 years.
Frequently Asked Questions
What is heart failure with preserved ejection fraction and why is it hard to treat?
HFpEF occurs when the heart’s pumping strength appears normal but it can’t relax and fill properly, making it difficult to pump enough blood during exercise. It’s hard to treat because the problem isn’t obvious on standard heart tests, and the underlying causes involve complex changes inside heart cells.
How do mitochondria relate to heart failure?
Mitochondria are the heart’s energy factories. When they malfunction, the heart can’t produce enough energy to meet demands, especially during activity. A 2026 study found that broken protein cleanup in mitochondria reduces energy production in HFpEF patients.
Can this research lead to new treatments for heart failure?
Potentially yes. By identifying that impaired protein quality control is the problem, researchers can now develop drugs targeting this specific mechanism. However, such treatments are still in early development stages and won’t be available for many years.
Should I change my treatment if I have heart failure?
No. This is fundamental research identifying a mechanism, not a clinical trial proving a new treatment works in humans. Continue following your cardiologist’s current recommendations. Discuss this research with your doctor if you’re interested in understanding your condition better.
Why does this type of heart failure mainly affect older people?
The research doesn’t fully explain this, but aging likely reduces the efficiency of the heart’s protein cleanup systems. The study used aged mice to model this age-related vulnerability, suggesting that accumulated damage over time contributes to the disease.
Want to Apply This Research?
- Track exercise tolerance by recording the maximum distance you can walk or the duration of activity before experiencing shortness of breath. Record weekly and note any improvements or declines over months.
- Users can log daily activities that stress the heart (climbing stairs, walking, exercise) and note energy levels afterward. This creates a personal baseline for cardiac reserve and helps identify patterns in exercise capacity that should be discussed with a cardiologist.
- Establish a monthly check-in where users review their activity logs with their healthcare provider. This long-term tracking helps detect subtle changes in cardiac reserve that might indicate disease progression or response to treatment adjustments.
This research describes mechanisms of heart disease in mice and does not represent approved human treatments. If you have heart failure or concerns about your heart health, consult your cardiologist before making any changes to your treatment plan. This article is for educational purposes and should not replace professional medical advice. The findings are preliminary and may not directly apply to human patients.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.